Literature DB >> 16107860

An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery.

S J Hedley1, A Auf der Maur, S Hohn, D Escher, A Barberis, J N Glasgow, J T Douglas, N Korokhov, D T Curiel.   

Abstract

Adenovirus (Ad) vectors are of utility for many therapeutic applications. Strategies have been developed to alter adenoviral tropism to achieve a cell-specific gene delivery capacity employing fiber modifications allowing genetic incorporation of targeting motifs. In this regard, single chain antibodies (scFv) represent potentially useful agents to achieve targeted gene transfer. However, the distinct biosynthetic pathways that scFv and Ad capsid proteins are normally routed through have thus far been problematic with respect to scFv incorporation into the Ad capsid. Utilization of stable scFv, which also maintain correct folding and thus functionality under intracellular reducing conditions, could overcome this restriction. We genetically incorporated a stable scFv into a de-knobbed, fibritin-foldon trimerized Ad fiber and demonstrated selective targeting to the cognate epitope expressed on the membrane surface of cells. We have shown that the scFv employed in this study retains functionality and that stabilizing the targeting molecule, per se, is critical to allow retention of antigen recognition in the adenovirus capsid-incorporated context.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16107860     DOI: 10.1038/sj.gt.3302603

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  21 in total

1.  Targeting adenoviruses with factor x-single-chain antibody fusion proteins.

Authors:  Christopher Y Chen; Shannon M May; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

Review 2.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

Review 3.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

4.  A strategy for adenovirus vector targeting with a secreted single chain antibody.

Authors:  Joel N Glasgow; Galina Mikheeva; Victor Krasnykh; David T Curiel
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

5.  Adenovirus fiber shaft contains a trimerization element that supports peptide fusion for targeted gene delivery.

Authors:  Jiali Li; Sonya Lad; Guang Yang; Yunping Luo; Milena Iacobelli-Martinez; F James Primus; Ralph A Reisfeld; Erguang Li
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

6.  Production and characterization of a humanized single-chain antibody against human integrin alphav beta3 protein.

Authors:  Dabin Liu; Chen Wang; Cun Li; Xin Zhang; Baozhong Zhang; Zhiqiang Mi; Xiaoping An; Yigang Tong
Journal:  J Biol Chem       Date:  2011-05-23       Impact factor: 5.157

7.  A Genetically Modified Adenoviral Vector with a Phage Display-Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma.

Authors:  Julius W Kim; J Robert Kane; Jacob S Young; Alan L Chang; Deepak Kanojia; Ramin A Morshed; Jason Miska; Atique U Ahmed; Irina V Balyasnikova; Yu Han; Lingjiao Zhang; David T Curiel; Maciej S Lesniak
Journal:  Hum Gene Ther       Date:  2015-08-11       Impact factor: 5.695

8.  Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid.

Authors:  J Vellinga; J de Vrij; S Myhre; T Uil; P Martineau; L Lindholm; R C Hoeben
Journal:  Gene Ther       Date:  2007-02-01       Impact factor: 5.250

9.  Transduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapy.

Authors:  Travis B Lewis; Joel N Glasgow; Anya M Glandon; David T Curiel; David G Standaert
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

Review 10.  Retargeting adenoviruses for therapeutic applications and vaccines.

Authors:  Michael A Barry; Jeffrey D Rubin; Shao-Chia Lu
Journal:  FEBS Lett       Date:  2020-02-03       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.